Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us



Call for Abstracts           Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
 
Daily Schedule:
Tue. 12/10/2013
Wed. 12/11/2013
Thu. 12/12/2013
Fri. 12/13/2013
Sat. 12/14/2013
 
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
 
Poster Session OT1
Poster Session OT2
Poster Session OT3
 
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6
 

Program Schedule   >  Poster Sessions - Poster Discussion 5

Poster Discussion 5 
   
  Novel Targets and Agents
PD5-1 The type II TGFβ receptor neutralizing antibody, TR1, abrogates the tumor-initiating cell (TIC) population in triple negative breast cancer (TNBC) via inhibition of SMAD and non-SMAD pathways
Bhola N, Arteaga C. Vanderbilt-Ingram Cancer Centre, Nashville, TN.
PD5-2 Preclinical assessment of HDAC inhibitor entinostat combined with all trans retinoic acid (ATRA) in aromatase inhibitor resistant breast cancer
Shah P, Sabnis G, Goloubeva O, Kazi A, Schech A, Gau Y, Chumsri S, Brodie A. University of Maryland School of Medicine, Baltimore, MD; Loyola University, Baltimore, MD. Preeti Shah is a recipient of an AACR Scholar-In-Training Award
PD5-3 Anti-metastatic activity, chemotherapeutic enhancement and therapeutic potential of targeting Hsp90 with ganetespib in triple negative breast cancer
Proia DA, Zhang C, Sequeira M, Jimenez J-P, He S, Nagai M, Acquaviva JL, Smith DL, Sang J, El-Hariry I. Synta Pharmaceuticals, Lexington, MA.
PD5-4 Withdrawn
PD5-5 Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC)
Melichar B, DeMichele A, Adenis A, Bourbouloux E, Tan-Chiu E, Niu H, Schusterbauer C, Dansky Ullmann C, Zhang B, Benaim E. Fakultní Nemocnice Olomouc – Onkologická Klinika, Olomouc, Czech Republic; University of Pennsylvania, Philadelphia, PA; Centre Oscar Lambret, Lille Cedex, France; Institut de Cancérologie de l'Ouest, Nantes, France; Plantation - Florida Cancer Research Institute (Florida Cancer Care), Plantation, FL; Millennium: The Takeda Oncology Company, Cambridge, MA.
PD5-6 Sustained hyperactivated mTOR & JAK2/STAT3 pathways in inflammatory breast cancer (IBC): Evidence for mTOR plus JAK2 therapeutic targeting
Jhaveri K, Teplinsky E, Arzu R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Silvera D, Levine PH, Hashmi S, Hoffman HJ, Paul L, Singh B, Goldberg JD, Hochman T, Formenti S, Valeta A, Moran MS, Schneider RJ. New York University School of Medicine, New York, NY; The Brooklyn Hospital Center; The George Washington University; Yale University School of Medicine.
PD5-7 Phase Ib study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with weekly paclitaxel in patients with advanced solid tumors: Safety and efficacy results, including breast cancer cohort
Dienstmann R, Adamo B, Vidal L, Dees EC, Chia S, Mayer EL, Baney TS, Dhuria S, Sen SK, Papoutsakis D, Cameron S, Infante JR. Vall d'Hebron University Hospital, Universitat Autňnoma de Barcelona, Barcelona, Spain; Hospital Clinic Provincial, Barcelona, Spain; Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada; Dana-Faber Cancer Institute, Boston, MA; Novartis Pharmaceuticals Corp., East Hanover, NJ; Novartis Pharmaceuticals Corp., Cambridge, MA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN.
PD5-8 Phase I clinical trial of neoadjuvant BIBF1120 plus weekly paclitaxel (P) in early HER-2 negative breast cancer. CNIO-BR-01-2010/GEICAM 2010-10 study
Quintela-Fandino M, Urruticoechea A, Guerra J, Gil M, González-Martin A, Marquez R, Hernandez-Agudo E, Rodríguez-Martin C, Gil M, Bratos R, Escudero MJ, Colomer R. CNIO - Spanish National Cancer Research Center, Madrid; MD Anderson Cancer Center, Madrid, Spain; ICO - Instituto Catalan Oncologia Duran y Reynals, Bellvitge - Barcelona, Spain; Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain; GEICAM - Spanish Breast Cancer Cooperative Group, Madrid, Spain.
   
 
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Call for Abstracts | Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
       line
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy